This is an automatically translated article.
Anzatax medicine is a cancer treatment drug, mainly used to treat ovarian cancer, adjuvant and alternative in breast cancer, some other types of cancer. So how should Anzatax 300mg/50ml be used?
1. What is Anzatax?
Anzatax medicine 300mg/50ml has the main ingredient is Paclitaxel 300mg/50ml and excipients just enough. The drug is prepared in the form of a concentrated solution for infusion.
This is an anti-cancer drug and is used in cancers such as ovarian cancer, breast cancer...
2. Uses of Anzatax
Indications for Anzatax 300mg/50ml
Ovarian cancer: paclitaxel is indicated for the treatment of patients with advanced or residual malignancy (> 1cm) after the initial surgical procedure, usually in combination with cisplatin. In the alternative chemotherapy of ovarian cancer, paclitaxel is indicated for the treatment of metastatic ovarian cancer after failure of first-line therapy. Breast Cancer: As adjuvant therapy, paclitaxel is indicated for the treatment of patients with lymphoma-positive breast cancer following anthracycline and cyclophosphamide (AC) therapy. Adjuvant therapy with the drug paclitaxel is considered an alternative to extended AC therapy. Paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer, either in combination with anthracycline, or in combination with trastuzumab. As monotherapy, treatment of metastatic breast cancer is indicated in patients who have not responded to standard anthracycline therapy or are unsuitable for anthracycline therapy. Advanced Non-Small Cell Lung Cancer (NSCLC): Paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are unable to undergo surgical intervention or radiation therapy. AIDS-associated Kaposi's Sarcoma (KS): Paclitaxel is also indicated for the treatment of patients with advanced AIDS-related Kaposi's sarcoma who have failed prior other drug therapy.
3. Usage and dosage of Anzatax 300mg/50ml
3.1 Administration The drug is administered by intravenous infusion:
Caution must be exercised before performing manipulation or infusion of the drug. The concentrated solution for solution for infusion must be diluted prior to administration and administered intravenously only. 3.2 Dosage The drug is prescribed and monitored by a doctor, below is a reference dose.
Ovarian cancer :
First-line treatment for patients with ovarian cancer: Start with 175 mg/m2 of paclitaxel intravenously over three hours, followed by 75mg/m2 of cisplatin and further treatment Follow-up is repeated after 3 weeks. Alternatively, a dose of 135 mg/m2 of paclitaxel should be administered intravenously over a 24-hour period, followed by 75 mg/m2 of cisplatin and the next course of treatment repeated after 3 weeks. Alternative treatment for ovarian cancer: The recommended dose of paclitaxel is 175 mg/m2 given over 3 hours, with a 3-week interval between episodes. Breast cancer:
Adjuvant chemotherapy for breast cancer: The recommended dose for paclitaxel is 175 mg/m2 given over 3 hours in 4 cycles, every 3 weeks, after AC therapy. First-line chemotherapy for breast cancer patients: When co-administering doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin administration. The recommended dose for paclitaxel is 220 mg/m2 intravenously over 3 hours, with a 3-week dosing interval between courses. When used in combination with trastuzumab, the recommended dose for paclitaxel is 175 mg/m2 by intravenous infusion over 3 hours, with a 3-week interval between courses, the paclitaxel infusion can be started on the following day at the same dose. first trastuzumab or immediately after subsequent doses of trastuzumab. Alternative for breast cancer: The recommended dose for paclitaxel is 175 mg/m2 given over a 3-hour period, with a 3-week interval between episodes. Non-small cell lung cancer:
The recommended dose for paclitaxel is 175 mg/m2 administered over 3 hours followed by 80 mg/m2 cisplatin, with a 3-week interval between courses. Treatment of AIDS-related Kaposi's sarcoma (KS):
The recommended dose of paclitaxel is 100 mg/m2 intravenously over 3 hours every 2 weeks.
4. Contraindications of the drug Anzatax 300mg/50ml
Anzatax medicine 300mg/50ml is contraindicated in the following cases:
Do not use Paclitaxel in patients who have had a serious hypersensitivity reaction to paclitaxel, maergalglyceral ricinaleate or to any component of the drug. Paclitaxel is contraindicated in nursing women. Do not use the drug in patients with primary neutropenia. Paclitaxel is contraindicated in patients with Kaposi's sarcoma with concomitant serious, uncontrolled infections. Patients with severe hepatic impairment should not be treated with paclitaxel.
5. Anzatax 300mg/50ml side effects
When taking the drug may encounter side effects including:
Very common side effects: Bacterial infections (mainly urinary tract infections and upper respiratory tract infections); Pseudomembranous colitis ; Myelosuppression, decreased neutrophil count, anemia, decreased platelet count, leukopenia, bleeding... Common: Bradycardia; Mild and transient nail and skin changes; Injection site reactions such as local edema, pain, erythema, induration, cellulitis, skin fibrosis and skin necrosis; Uncommon: Septic shock; Significant hypersensitivity reactions requiring treatment (eg, hypotension, angioedema, dyspnea, generalized urticaria, chills, back pain, chest pain, tachycardia, abdominal pain, headache in extremities , sweating and high blood pressure); Cardiomyopathy, asymptomatic ventricular tachycardia, tachycardia with brief episodes of double beats, atrioventricular block and syncope, myocardial infarction; Hypertension, thrombosis, thrombophlebitis Rare: Pneumonia, peritonitis, bacteremia; Febrile neutropenia; Anaphylactic reactions; dehydration; Dyspnea, pleural effusion, interstitial pneumonia, pulmonary fibrosis, pulmonary embolism, respiratory failure; Intestinal obstruction, intestinal perforation, ischemic colitis, pancreatitis; Itching, rash, erythema; Asthenia, restlessness, edema, fatigue. Laboratory test results: Usually a sharp increase in aminotransferases (AST and ALT); strongly increased alkaline phosphatase. Uncommon causes a sharp increase in bilirubin; Rarely causes increased serum creatinine. When taking the drug, if there is any abnormality, you should immediately notify the doctor for treatment.
6. Notes when using Anzatax 300mg/50ml
Paclitaxel should be administered under the supervision of healthcare professionals experienced in the use of cancer chemotherapy agents. Because severe hypersensitivity reactions can occur, appropriate assistive devices should be available.
Because of the potential for extravasation of the drug, it is important to closely monitor the infusion site for the possibility that extravasation during infusion causes cellulitis.
Patients must be on corticosteroids, antihistamines and H2 antagonists before starting treatment with paclitaxel.
Vital signs should be regularly monitored, especially during the first hour of paclitaxel infusion. Cardiac function monitoring should be considered when paclitaxel is used in combination with doxorubicin or trastuzumab for the initial treatment of metastatic breast cancer.
When paclitaxel is given by prolonged infusion, increased myelosuppression may be observed in patients with moderate to severe hepatic impairment. Patients should be closely monitored for the development of myelosuppression.
Special care should be taken to avoid intravascular administration of paclitaxel. In animal studies evaluating local tolerability, severe tissue reactions occurred following intra-arterial injection.
Pregnant women: Paclitaxel 6mg/ml concentrate for solution for infusion should not be used during pregnancy, unless the mother's clinical condition necessitates treatment with paclitaxel.
Lactation: It is not known whether paclitaxel is excreted in breast milk. Paclitaxel is contraindicated in nursing women. Breastfeeding should be discontinued during paclitaxel therapy.
The drug can cause confusion, hearing loss, tinnitus, dizziness, headache affecting concentration, so patients need to be careful when driving and operating machinery.
Drug Interactions
In the first-line treatment of patients with ovarian cancer, Paclitaxel must be given before cisplatin, tolerability will be similar to when Paclitaxel is used as monotherapy. If paclitaxel is administered after cisplatine, the myelosuppressive effect is more severe and paclitaxel clearance is reported to be reduced by 20% if paclitaxel is administered after cisplatin. The drug should not be diluted or stored or stored in PVC plastic containers (as this may lead to the release of DEHP) because the excipients contain huile de ricin polyoxyethylene. Anzatax is an anti-cancer drug that should be used under the guidance and close supervision of an experienced physician. When taking this medicine, if you have any unusual symptoms, you should tell your doctor or nurse immediately.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
